KISQALI (ribociclib) tablets
Kisqali is used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in premenopausal, perimenopausal, and postmenopausal women. Brand Name: KISQALI (ribociclib) tablets, for oral use Initial U.S. Approval: 2017
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
KISQALI (ribociclib) tablets
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor.
KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine-based therapy; or
• fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.
In the United States, ribociclib is indicated for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.
In the European Union, ribociclib is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
Drug (Brand / Generic): KISQALI / ribociclib
Current Indications: hormone receptor (HR)-positive
Marketed by:: Novartis Pharmaceuticals Corporation
Approval Date: 2017
Dosage forms and strengths of KISQALI (ribociclib).
• Tablets: 200 mg
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
